Pfizer (PFE) stock-based compensation was $799M in FY2025 (-9% YoY). The tables below show the complete quarterly and annual stock-based compensation history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Stock-Based Compensation
Fiscal Year
Stock-Based Compensation
YoY
2025
$799M
-9%
2024
$877M
+67%
2023
$525M
-40%
2022
$872M
-27%
2021
$1.2B
+54%
2020
$780M
+9%
2019
$718M
-24%
2018
$949M
+13%
2017
$840M
+22%
2016
$691M
+3%
2015
$669M
+14%
2014
$586M
+12%
2013
$523M
+9%
2012
$481M
+15%
2011
$419M
+3%
2010
$405M
+16%
2009
$349M
-9%
2008
$384M
-12%
2007
$437M
Recent Quarterly Stock-Based Compensation
Quarter
Stock-Based Compensation
Q2 2026
$249M
Q1 2026
$272M
Q4 2025
$225M
Q3 2025
$201M
Q2 2025
$203M
Q1 2025
$170M
Q4 2024
$177M
Q3 2024
$274M
Q2 2024
$206M
Q1 2024
$220M
Q4 2023
$121M
Q3 2023
$151M
Source: PFE on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.